Search

The animation and accompanying article aims to draw attention to and raise awareness about pulmonary fibrosis, a disease often misdiagnosed an overlooked.

European_Commission_approves_nintedanibSSc-ILD

Nintedanib is approved as the first and only treatment of systemic sclerosis-associated interstitial lung disease

ArisGlobal acquires Boehringer Ingelheim technology

Boehringer Ingelheim’s signal analytics technology is acquired by ArisGlobal

Boehringer Ingelheim and Fraunhofer partnership

Boehringer Ingelheim and Fraunhofer IME launch collaboration which aims to develop sustainable animal health products

New production center for Veterinary Public Health

Boehringer Ingelheim invests more than €200 million to establish a strategic production center for Veterinary Public Health in Lyon, France.

Approval for Aservo EquiHaler equine asthma therapy

Boehringer Ingelheim receives approval for Aservo® EquiHaler®, industry first equine asthma therapy

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

Phospholipid modulator

Vascular modulator

BI 764524: Sema3A antibody

Oxidase Inhibitor

BI 1291583: CatC Inhibitor

Modified yersinia

PD-1 antibody

BI 1569912

C3-binding polypeptide

Anti-fibrotic agent

Ion channel inhibitor

KRAS multi-inhibitor

Immunomodulator

NPY2r agonist

BI 765845: Heart disease modulator | Myocardial infarction

IL11 antibody

Lysophospholipase inhibitor

12th Expert Forum on Farm Animal Well-Being

Boehringer Ingelheim Venture Fund invests precision antimicrobials

Breathing hope: fighting the lung disease pulmonary fibrosis

European_Commission_approves_nintedanibSSc-ILD

ArisGlobal acquires Boehringer Ingelheim technology

Boehringer Ingelheim and Fraunhofer partnership

New production center for Veterinary Public Health

Approval for Aservo EquiHaler equine asthma therapy